Your browser is no longer supported. Please, upgrade your browser.
ALLK Allakos Inc. daily Stock Chart
Allakos Inc.
Index- P/E- EPS (ttm)-1.49 Insider Own- Shs Outstand45.48M Perf Week4.99%
Market Cap3.98B Forward P/E- EPS next Y-2.38 Insider Trans- Shs Float43.45M Perf Month162.29%
Income-64.70M PEG- EPS next Q-0.42 Inst Own91.10% Short Float13.42% Perf Quarter100.37%
Sales- P/S- EPS this Y-73.60% Inst Trans5.70% Short Ratio8.62 Perf Half Y132.22%
Book/sh3.53 P/B24.79 EPS next Y-38.40% ROA-34.40% Target Price100.67 Perf Year121.24%
Cash/sh3.37 P/C25.99 EPS next 5Y- ROE-37.00% 52W Range29.34 - 92.84 Perf YTD67.40%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-5.75% Beta-
Dividend %- Quick Ratio16.60 Sales past 5Y- Gross Margin- 52W Low198.23% ATR5.57
Employees68 Current Ratio16.60 Sales Q/Q- Oper. Margin- RSI (14)74.22 Volatility5.63% 8.06%
OptionableYes Debt/Eq0.00 EPS Q/Q-98.70% Profit Margin- Rel Volume0.51 Prev Close89.73
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume676.55K Price87.50
Recom1.70 SMA2031.13% SMA5074.27% SMA20090.41% Volume343,721 Change-2.49%
Aug-13-18Initiated William Blair Outperform
Aug-13-18Initiated Jefferies Buy $53
Aug-13-18Initiated Goldman Neutral $31
Aug-13-19 05:20AM  Will Allakos Continue to Surge Higher? Zacks
Aug-09-19 10:09AM  Top Ranked Momentum Stocks to Buy for August 9th Zacks
Aug-07-19 12:11PM  A Look At Benzinga Pro's Most-Searched Tickers For August 7, 2019 Benzinga +10.10%
Aug-06-19 10:18PM  Allakos Announces Upsizing and Pricing of Public Offering of Common Stock GlobeNewswire +21.77%
Aug-05-19 04:29PM  Allakos Announces Proposed Public Offering of Common Stock GlobeNewswire +110.52%
12:21PM  A Look At Benzinga Pro's Most-Searched Tickers For August 5, 2019 Benzinga
10:34AM  Pharma Stock Set to Double Today Schaeffer's Investment Research
10:34AM  Small Biotech Doubles as Drug Shows Promise in Rare Diseases Bloomberg
07:15AM  Allakos Reports Second Quarter 2019 Financial Results GlobeNewswire
07:09AM  Allakos Stock Doubles on Positive Stomach Disease Drug Study Data
07:00AM  Allakos Announces AK002 Met All Prespecified Primary and Secondary Endpoints in Phase 2 Randomized, Double-Blind, Placebo-Controlled Study in Patients with Eosinophilic Gastritis (EG) and/or Eosinophilic Gastroenteritis (EGE) GlobeNewswire
Jul-24-19 01:40PM  Imagine Owning Allakos (NASDAQ:ALLK) And Wondering If The 17% Share Price Slide Is Justified Simply Wall St.
Jun-19-19 07:10AM  Ohio Capital Fund's management firm seeks 3-year extension, raise American City Business Journals
May-08-19 08:01AM  Allakos Reports First Quarter 2019 Financial Results GlobeNewswire
May-07-19 04:01PM  Allakos Announces Positive Results with AK002 in Patients with Severe Allergic Conjunctivitis GlobeNewswire
May-01-19 12:17PM  Is Allakos Inc. (ALLK) A Good Stock To Buy? Insider Monkey
Mar-14-19 04:01PM  Allakos Reports Fourth Quarter and Full Year 2018 Financial Results and 2018 Corporate Highlights GlobeNewswire
Mar-11-19 11:54AM  State-backed VC vehicle managers aren't worried about dipping into tax credits here's why American City Business Journals +6.57%
Feb-19-19 08:00AM  Allakos Announces Positive Phase 1 Results with AK002 in Indolent Systemic Mastocytosis GlobeNewswire
Feb-14-19 06:11AM  Allakos Enters Oversold Territory Zacks
Feb-11-19 08:00AM  Allakos Announces Positive Phase 2 Results for AK002 in Patients with Xolair Refractory Chronic Spontaneous Urticaria and Provides Additional Data from Chronic Urticaria Study Cohorts GlobeNewswire -10.46%
Feb-04-19 08:00AM  Allakos to Host Investor Day on February 19 in New York City GlobeNewswire
Jan-29-19 08:00AM  Allakos Announces Positive Phase 2 Results in Patients with Cholinergic Urticaria and Symptomatic Dermographism GlobeNewswire -7.70%
Jan-07-19 08:00AM  Allakos Announces Positive Phase 2 Results in a Cohort of Xolair-Naïve Chronic Spontaneous Urticaria Patients GlobeNewswire -7.85%
Jan-02-19 01:15PM  Here are the winners and losers from Bay Area's IPO class of 2018 American City Business Journals
Dec-27-18 08:14AM  5 Best-Performing IPOs of 2018 Zacks
Dec-21-18 07:24PM  Assessing the Performance of 2018s Major IPOs
08:49AM  Allakos (ALLK) Catches Eye: Stock Jumps 6.5% Zacks
Nov-26-18 02:03PM  Here's how much better insiders have profited from this year's IPO boom American City Business Journals
Nov-22-18 12:19PM  Has Allakos Inc (NASDAQ:ALLK) Got Enough Cash? Simply Wall St.
Nov-21-18 07:30AM  New Research Coverage Highlights TheStreet, EVO Payments, Odyssey Marine Exploration, Allakos, SORL Auto Parts, and SPAR Group Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-08-18 04:01PM  Allakos Announces Clinical Update and Third Quarter 2018 Financial Results GlobeNewswire
Oct-08-18 08:00AM  Allakos Presents Data from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2018 Annual Scientific Meeting GlobeNewswire
Aug-29-18 04:01PM  Allakos Announces Second Quarter 2018 Financial Results GlobeNewswire
Aug-13-18 02:52PM  Mixed Reviews For Allakos As Sell-Side Starts Coverage Of Biotech Benzinga
Jul-24-18 08:00AM  Allakos Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +5.04%
Jul-19-18 01:50PM  Biotech Allakos shares surge more than 70% in trading debut MarketWatch
11:31AM  [$$] Health-Care Companies Keep Up Rapid Pace of IPOs The Wall Street Journal
07:50AM  Biotech Allakos prices IPO at $18, above price range MarketWatch
07:00AM  Allakos Announces Pricing of Initial Public Offering GlobeNewswire
Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in Redwood City, California.